These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 38159967)
1. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma. Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967 [TBL] [Abstract][Full Text] [Related]
2. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma. Lu H; Liu JF; Rong Y; Liu XB; Wang Y J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232 [TBL] [Abstract][Full Text] [Related]
3. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy for Node-positive Esophageal Squamous Cell Carcinoma Improves Survival. Feng SK; Liu XB; Xing WQ; Liu Y; Chen PN; Jiang D; Sun HB Ann Thorac Surg; 2022 Oct; 114(4):1205-1213. PubMed ID: 34626616 [TBL] [Abstract][Full Text] [Related]
5. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial). Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study. Guo JC; Huang TC; Kuo HY; Lin CC; Hsu FM; Cheng JC; Huang YL; Hsieh MS; Huang PM; Lee JM; Wu SL; Hsu CH Cancer Immunol Immunother; 2024 Sep; 73(11):230. PubMed ID: 39249605 [TBL] [Abstract][Full Text] [Related]
7. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis. Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662 [TBL] [Abstract][Full Text] [Related]
8. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of nodal status and lymphovascular invasion in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Miyata H; Sugimura K; Kanemura T; Takeoka T; Sugase T; Yasui M; Nishimura J; Wada H; Akita H; Yamamoto M; Hara H; Shinno N; Omori T; Yano M Dis Esophagus; 2024 Aug; 37(9):. PubMed ID: 38693752 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382 [TBL] [Abstract][Full Text] [Related]
11. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy. Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278 [TBL] [Abstract][Full Text] [Related]
12. Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer. Hirahara N; Matsubara T; Kaji S; Hayashi H; Kawakami K; Sasaki Y; Takao S; Takao N; Hyakudomi R; Yamamoto T; Tajima Y BMC Cancer; 2022 Jun; 22(1):718. PubMed ID: 35768866 [TBL] [Abstract][Full Text] [Related]
13. Minimally Invasive Esophagectomy with Thoracic Duct Resection Post Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus-Impact on Lymph Node Yield and Hemodynamic Parameters. Anand S; Kalayarasan R; Chandrasekar S; Gnanasekaran S; Pottakkat B J Gastrointest Cancer; 2019 Jun; 50(2):230-235. PubMed ID: 29344808 [TBL] [Abstract][Full Text] [Related]
14. Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study. Park JK; Kim JJ; Moon SW; Cho DG J Cardiothorac Surg; 2018 Jun; 13(1):62. PubMed ID: 29880029 [TBL] [Abstract][Full Text] [Related]
15. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery. Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482 [TBL] [Abstract][Full Text] [Related]
16. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sakai M; Miyazaki T; Fukuchi M; Kuwano H In Vivo; 2019; 33(2):501-506. PubMed ID: 30804133 [TBL] [Abstract][Full Text] [Related]
17. Influence of Induction Therapy on Robot-Assisted McKeown Esophagectomy for Esophageal Squamous Cell Carcinoma. Duan X; Gong L; Yue J; Shang X; Ma Z; Tang P; Chen C; Jiang H; Yu Z Dig Surg; 2020; 37(6):463-471. PubMed ID: 32728007 [TBL] [Abstract][Full Text] [Related]
18. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M; N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008 [TBL] [Abstract][Full Text] [Related]
20. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer. Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q Front Immunol; 2023; 14():1066527. PubMed ID: 36825006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]